Glucose transporter 1 (GLUT1), encoded by the SLC2A1 gene, is a vital element in the glucose transport of malignant cells, and abnormally expressed in a great number of human solid cancers. But the association between GLUT1 overexpression and clinical outcome in gastric cancer setting remains to be clarified. Therefore, we carried out this study to evaluate the correlation between GLUT1 expression and clinicopathological and prognostic characteristics in gastric cancer.
The mRNA level of GLUT1 expression in different subtypes of gastric cancer was assessed by using Oncomine database. The correlation between GLUT1 expression levels and clinical survival in gastric cancer patients with diverse clinicopathologic parameters was analyzed by using Kaplan-Meier plotter database. The COSMIC and cBioPortal databases were used for analysis of GLUT1 mutation characteristics and alteration frequency.
Oncomine database showed elevated expression of GLUT1 in different subtypes of gastric cancer. Prognostic analysis revealed that elevated expression status of GLUT1 mRNA was associated with poor overall survival and first progression survival of gastric cancer patients. Low alteration frequency was observed in gastric cancer.
GLUT1 is upregulated in gastric cancer, and its overexpression is related with unfavorable clinical survival, indicating that GLUT1 expression is a significant prognostic biomarker of gastric cancer.
Dr. Ji Wang
National Natural Science Foundation of China (No. 81602471 and No. 81672729) and by grant from Sub project of China National Program on Key Basic Research Project (973 Program) (No. 2014CB744505).
All authors have declared no conflicts of interest.